David P. Schenkein, Director at Denali Therapeutics Inc. (DNLI), sold 118,882 shares at $32.09 ($3.9M) on 2024-11-11, disclosed to the SEC on 2024-11-13.
Scheduled sale ($3.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.09 | 27,129 | $871K | 22.5% |
| 2 | $32.09 | 27,129 | $871K | 22.5% |
| 3 | $32.87 | 32,312 | $1.1M | 27.5% |
| 4 | $32.87 | 32,312 | $1.1M | 27.5% |
| Total | $32.51 avg | 118,882 | $3.9M | 100% |
| Filing → |
| AGIO | SELL | 2023-04-05 | $748K | — | Filing → |
| AGIO | SELL | 2023-03-29 | $443K | — | Filing → |
| AGIO | SELL | 2023-03-15 | $862K | — | Filing → |